Search Result

Results for "

LYTAC

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Asialoglycoprotein Receptor (ASGPR) (1) Drug Intermediate (2) EGFR (1) HSP (2) LYTACs (12) PD-1/PD-L1 (1) PSMA (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Metabolic Disease (3)
Click Chemistry:	DBCO (1)

Inhibitors & Agonists

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148476

Tri-GalNAc-DBCO	LYTACs	Metabolic Disease
Tri-GalNAc-DBCO is a synthetic ligand composed of three GalNAc units connected to DBCO. Tri-GalNAc-DBCO can act as a ligand for the sialic acid-degrading protein receptor (ASGPR), and can be coupled with targeting proteins or small molecules to form GalNAc-LYTACs. Tri-GalNAc-DBCO specifically binds to ASGPR and, through receptor-mediated endocytosis, guides the coupled molecules to lysosomes for degradation .

HY-148118A

Tri-GalNAc(OAc)3 TFA	LYTACs	Cancer
Tri-GalNAc(OAc)3 TFA is a trivalent N-acetylgalactosamine (GalNAc) derivative that can be used to synthesize GalNAc-LYTAC. Tri-GalNAc is a specific ligand targeting the asialoglycoprotein receptor (ASGPR), mediating the endocytosis and transport of cell surface proteins (such as EGFR, HER2) to lysosomes for degradation by lysosomal targeting chimeras (LYTACs). Tri-GalNAc significantly reduces the level of target proteins and inhibits downstream signaling pathways (such as EGFR-mediated Akt and MAPK signals). Tri-GalNAc(OAc)3 TFA can be used for hepatocyte targeting studies, and can degrade carcinogenic membrane proteins and inhibit tumor cell proliferation in liver cancer cell models .

HY-148118

Tri-GalNAc(OAc)3	LYTACs	Cancer
Tri-GalNAc(OAc)3 is a trivalent N-acetylgalactosamine (tri-GalNAc) derivative, which can be used as a linker to synthesize LYTACs .

HY-139482

tri-GalNAc-COOH	LYTACs	Cancer
tri-GalNAc-COOH is an asialoglycoprotein receptor (ASGPR) ligand that can be used for LYsosome TArgeting Chimera (LYTAC) research .

HY-147354

TriGalNAc CBz	LYTACs	Cardiovascular Disease
TriGalNAc CBz is a GalNAc derivative and tri-GalNAc is an asialoglycoprotein receptor (ASGPR) ligand. TriGalNAc CBz can be used for mRNA drug delivery as well as lysosomal targeted chimerism (LYTAC) studies .

HY-147102

tri-GalNAc biotin	LYTACs	Metabolic Disease
tri-GalNAc biotin is a biotinylated ASGPR (Asialoglycoprotein receptor) ligand. tri-GalNAc biotin promotes cellular uptake of neutravidin (NA) via ASGPR. tri-GalNAc biotin delivers neutravidin to lysosomes for degradation. tri-GalNAc biotin can be used for research of LYsosome TArgeting Chimera (LYTAC) .

HY-145368B

Tri-GalNAc(OAc)3-Perfluorophenyl	LYTACs	Metabolic Disease
Tri-GalNAc(OAc)3-Perfluorophenyl is a pentafluorophenyl modified Tri-GalNAc(OAc)3 (HY-148118), a tri-GalNAc ligand that can be used for the synthesis of GalNAc-LYTAC. GalNAc-LYTAC engages the asialoglycoprotein receptor for targeted protein degradation.Tri-GalNAc(OAc)3-Perfluorophenyl can be used for the study of liver metabolism .

HY-171910

tri(GalNAc-PEG2)-PEG4-cyclo(Ac-DCAW-{Arg(3F-Ph)-PEG2}-LGELVWCT) (Cys2-Cys12)	Asialoglycoprotein Receptor (ASGPR) LYTACs	Others
tri(GalNAc-PEG2)-PEG4-cyclo(Ac-DCAW-{Arg(3F-Ph)-PEG2}-LGELVWCT) (Cys2-Cys12) is an asialoglycoprotein receptor (ASGPR) ligand that can be used for LYsosome TArgeting Chimera (LYTAC) research .

HY-145013

tri-GalNAc-COOH (acetylation)	LYTACs	Others
tri-GalNAc-COOH acetylation is the acetylated and modified form of tri-GalNAc-COOH. tri-GalNAc-COOH acetylation can be used for the synthesis of LYTAC.

HY-174476

HSP90i	HSP Drug Intermediate	Cancer
HSP90i is a HSP90 inhibitor. HSP90i can be used as a drug intermediate to synthesize LYTACs, such as dPDL1-4 (HY-174468) .

HY-174799

HSP90i-COCH2CH2-PEG4-NHBoc	HSP	Cancer
HSP90i-COCH2CH2-PEG4-NHBoc is a conjugate of the HSP90 Ligand (HY-174476) and the linker (HY-W021787). HSP90i-COCH2CH2-PEG4-NHBoc can be used for synthesis of LYTACs, such as dPDL1-4 (HY-174468) .

HY-164396

Allyl-mannose-6-phosphonate	Drug Intermediate LYTACs	Cancer
Allyl-mannose-6-phosphonate (M6Pn; Compound 6) is a stable analogue of mannose-6-phosphate (M6P). Allyl-mannose-6-phosphonate can be used to synthesize M6Pn-peptide conjugates and construct lysosome-targeting chimeras (LYTAC) .

HY-181830

Atz-L5	PD-1/PD-L1 PSMA LYTACs	Cancer
Atz-L5 is a PD-L1 PTAC (PSMA-targeted chimera) degrader (DC₅₀: 18 pM in PC3-PIP cells; 2 pM in LNCaP cells) and *LYTAC. Atz-L5 promotes lysosomal degradation of PD-L1* in PSMA-positive prostate cancer cells. Atz-L5 is applicable to the research of prostate cancer .

HY-181829

Ctx-L3	EGFR PSMA LYTACs	Cancer
Ctx-L3 is a selective EGFR PTAC (PSMA-targeted chimera) degrader (DC₅₀: 4.3 pM in LNCaP cells) and *LYTAC. Ctx-L3 recruits prostate-specific membrane antigen (PSMA) and mediates lysosomal degradation of EGFR* in PSMA-positive prostate cancer cells. Ctx-L3 exhibits degrading activity against EGFR in prostate cancer cells. Ctx-L3 is applicable to related research on prostate cancer .

Cat. No.	Product Name		Classification

HY-148476

Tri-GalNAc-DBCO		DBCO
Tri-GalNAc-DBCO is a synthetic ligand composed of three GalNAc units connected to DBCO. Tri-GalNAc-DBCO can act as a ligand for the sialic acid-degrading protein receptor (ASGPR), and can be coupled with targeting proteins or small molecules to form GalNAc-LYTACs. Tri-GalNAc-DBCO specifically binds to ASGPR and, through receptor-mediated endocytosis, guides the coupled molecules to lysosomes for degradation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.